New Milestone in 3D Printed Bioresorbable Dental Implants

Australian-Singaporean Partnership Achieves Key Milestones

SINGAPORE: Bioresorbable implants manufacturer Osteopore has announced significant progress in its joint $18.7 million program with the National Dental Centre Singapore (NDCS) and the Agency for Science, Technology and Research (A*STAR). The Singapore-Australian collaboration aims to develop 3D printed bioresorbable dental implants to aid bone healing and boost the success of tooth implant surgeries.

Innovative Approach to Accelerate Bone Regeneration

Osteopore, known for its Osteoplug and Osteomesh bioresorbable implants that encourage bone regeneration, has successfully combined patented biological additives and polymer compounds. The company reported positive results from testing, demonstrating no adverse reactions and good biocompatibility. As stated by Osteopore, “Adverse reaction testing demonstrated that the successful combination of patented biological additives and polymer compounds was non-cytotoxic, showing no adverse reactions and good biocompatibility.”

Goh Bee Tin: Running The Next Lap in Singapore’s Oral Health

Promising Results for Bone Growth

According to the announcement, osteogenic differentiation testing, which indicates bone growth, showed enhanced viability and osteogenic differentiation capabilities. “Moreover, osteogenic differentiation testing showed enhanced viability and osteogenic differentiation capabilities, indicating both osteogenic differentiation and higher osteogenic differentiation,” the company stated.

Next Phase: In Vivo Studies

With these promising results, the next-generation dental implant project is now set to progress towards in vivo studies in biological models. Osteopore CEO Dr. Yujing Lim expressed excitement about the project’s outcomes and appreciation for the support from partners at ASTAR and NDCS. “We are excited by the outcomes of this project so far and appreciate the support of our partners at ASTAR and NDCS,” Dr. Lim said.

Long-Term Vision and Commercialization

While Osteopore continues to prioritize the commercialization of its current products, the company looks forward to working on new technologies, such as the next-generation jaw implant, which supports its long-term vision of becoming the global leader in regenerative medicine. “We are delighted with the dedication of our partners towards ensuring that project milestones are met. While we continue to prioritise our objective of commercialising our current products, we are looking forward to working on new technologies – such as the next-generation jaw implant which supports our long-term vision of becoming the global leader in regenerative medicine,” Dr. Lim added.

Profile: Singapore’s Dental Services and Market